Hui-Gene Therapeutics
Fangxin Li currently serves as the China General Manager at HuidaGene Therapeutics since June 2025. Previous roles include being a Member of the Board of Directors for CANbridge Pharmaceuticals Inc. and Hua Medicine, as well as working in investment and venture creation at WuXi AppTec from April 2021 to June 2025. Prior experience also includes a consultancy position at Bain & Company focusing on healthcare strategy and commercial due diligence, and serving as the Founding CEO of HAIKUI Regenerative Medicine, where significant advancements were made in preclinical trials for cartilage and dermal products. Fangxin Li holds a Doctor of Philosophy (Ph.D.) in Tissue Engineering from the University of Oxford and a Bachelor of Engineering from Imperial College London.
This person is not in any teams
This person is not in any offices
Hui-Gene Therapeutics
Hui-Gene is focused on R&D for single-gene disorders and has developed pilot pipes in neurodegenerative diseases.